ProCE Banner Activity

Phase I Dose-Escalation Study of Mitapivat (AG-348) in Patients With Sickle Cell Disease

Slideset Download
Conference Coverage
Results from a phase I trial of mitapivat reporting evidence of increased hemoglobin levels, improved oxygen affinity, decreased markers of hemolysis, and decreased sickling rate.

Released: December 17, 2021

Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo Inc

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp

Novartis Pharmaceuticals Corporation